Israel's OrSense has closed an $18 million financing round led by Israel Healthcare Ventures. Other participants in the financing included STAR Ventures and Lewis Trust Private Equity division. The funds raised will be used to accelerate the commercialization of the company's products for non-invasive monitoring of various blood parameters.
"Anemia is a key undiagnosed and untreated condition affecting around two billion people worldwide, [who] may benefit from a painless, safe and easy to use screening solution," says OrSense's CEO Lior Ma'ayan in a statement.
"The funds secured will allow us to expand our commercialization efforts into additional point of care segments such as women's health, public health programs and homecare. During 2011 we will expand our geographical reach beyond Europe to Asia Pacific, Africa and the Americas."